Antibodies are considered as an excellent foundation to neutralize pathogens and as highly specific therapeutic agents. Antibodies are generated in response to a vaccine but little use as immunotherapy to combat virus infections. A new generation of broadly cross-reactive and highly potent antibodies has led to a unique chance for them to be used as a medical intervention. Neutralizing antibodies (monoclonal and polyclonal antibodies) are desirable for pharmaceutical products because of their ability to target specific epitopes with their variable domains by precise neutralization mechanisms. The isolation of neutralizing antiviral antibodies has been achieved by Phage displayed antibody libraries, transgenic mice, B cell approaches, and hybridoma technology. Antibody engineering technologies have led to efficacy improvements, to further boost antibody in vivo activities. “Although neutralizing antiviral antibodies have some limitations that hinder their full development as therapeutic agents, the potential for prevention and treatment of infections, including a range of viruses (HIV, Ebola, MERS-COV, CHIKV, SARS-CoV, and SARS-CoV2), are being actively pursued in human clinical trials.”

抗体被认为是中和病原体的良好基础和高度特异性的治疗剂。抗体是针对疫苗产生的，但很少用作对抗病毒感染的免疫疗法。新一代广泛交叉反应且高效的抗体为它们用作医疗干预提供了独特的机会。中和抗体（单克隆和多克隆抗体）是医药产品所需要的，因为它们能够通过精确的中和机制利用其可变域靶向特定表位。中和抗病毒抗体的分离已通过噬菌体展示抗体库、转基因小鼠、B细胞方法和杂交瘤技术实现。抗体工程技术带来了功效的提高，进一步增强了抗体的体内活性。 “尽管中和抗病毒抗体存在一些限制，阻碍其作为治疗药物的全面发展，但其预防和治疗感染的潜力，包括一系列病毒（HIV、埃博拉、MERS-COV、CHIKV、SARS-CoV 和 SARS-CoV2） ），正在积极开展人体临床试验。”